Skip to main content

Table 1 Baseline characteristics of 21 included patients

From: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer

Patient

Gender

Age

TNM

Stage

Pathology

Volume (cm3)

CTV 66Gy

BTV FDG 40%

BTV FDG 70%

BTV FMISO

BTV FDG perRT

1

F

51

T3N3M0

IIIB

Adenocarcinoma

157.2

21.1

3.0

1.9

18.7

2

M

64

T4N0M0

IIIA

Squamous cell carcinoma

512.6

186.5

6.9

75.3

162.0

3

F

59

T1N2M0

IIIA

Adenocarcinoma

68.5

9.9

7.6

2.4

2.3

4

M

51

T1N3M0

IIIB

Adenocarcinoma

45.8

15.1

2.4

0.1

5.1

5

M

59

T3N3M0

IIIB

Adenocarcinoma

273.2

87.2

6.4

8.3

78.7

6

F

60

T3N2M0

IIIA

Adenocarcinoma

648.7

189.5

6.1

143.1

132.1

7

M

76

T2N0M0

IIA

Squamous cell carcinoma

56.8

13.8

5.0

2.3

2.8

8

F

62

T2N2M0

IIIA

Squamous cell carcinoma

116.3

6.3

0.2

4.4

1.1

9

M

63

T4N1M0

IIIA

Squamous cell carcinoma

236.1

19.2

0.2

5.7

8.9

10

M

65

T4N2M0

IIIB

Squamous cell carcinoma

157.4

14.9

0.3

26.1

9.1

11

M

72

T3N2M0

IIIA

Squamous cell carcinoma

289.4

101.1

19.1

272.5

75.8

12

M

59

T4N3M0

IIIB

Squamous cell carcinoma

290

37.2

7.6

36.8

15.4

13

M

55

T4N2M0

IIIB

Squamous cell carcinoma

970.9

353.2

6.7

100.8

87.6

14

M

58

T4N0M0

IIIB

Squamous cell carcinoma

283.7

72.6

15.1

81.1

34.0

15

M

45

T3N2M0

IIIA

Squamous cell carcinoma

80.5

30.5

0.4

16.1

9.2

16

M

54

T2N2M0

IIIA

Adenocarcinoma

64.4

9.4

0.6

2.4

5.1

17

M

61

T4N2M0

IIIB

Squamous cell carcinoma

241.1

22.6

0.9

24.2

64.4

18

M

58

T3N0M0

IIB

Unknow

90.4

8.8

2.5

7.9

9.1

19

M

63

T2N2M0

IIIA

Adenocarcinoma

328.8

9.5

0.5

1.8

10.2

20

M

70

T3N2M0

IIIA

Squamous cell carcinoma

135

24.3

1.6

0.2

4.8

21

M

42

T0N2M0

IIIA

Unknow

82.1

29.4

8.0

2.8

19.7

mean

 

59

   

244.2

60.1

4.8

38.9

36

SE

 

8

   

49.6

18.8

1.1

14.5

10.1